1255649-22-9

Upstream product

• 374-01-6 1,1,1-trifluoroisopropanol 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 1255649-26-3 (rac)-4-(2,2,2-trifluoro-1-methyl-ethoxy)-phenylamine 
• 1274888-48-0 (rac)-methyl-[4-(2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-amine 
• 1274888-43-5 (rac)-ethyl-[4-(2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-amine 

Relevant academic research and scientific papers

NEW AZACYCLIC COMPOUNDS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3 and A are as described herein, compositions including the compounds and methods of using the compounds.

NEW AZACYCLIC COMPOUNDS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3 and A are as described herein, compositions including the compounds and the compounds for use as inhibitors of hormone sensitive lipa

NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES

The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof, wherein A1, A2, R1, R2, R3, R4, R5 and R6 have the significance given herein.

HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES

Compounds of formula (I), as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein A1, A2, R1,R2 R3,R4 R5 and R6 have the significance given in claim 1. Objects of the present invention are the compounds of formula (I) and their aforementioned salts and esters and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments containing the said compounds, their pharmaceutically acceptable salts or esters, the use of the said compounds, salts or esters for the treatment or prophylaxis of illnesses, especially in the treatment or prophylaxis of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis or obesity and the use of the said compounds, salts or esters for the production of medicaments for the treatment or prophylaxis of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis or obesity.

SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES

Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions as HSL inhibitors for the treatment of diabetes, wherein R1,R2, R3, Ca and Cb have the significance given in claim 1.

NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES

The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof. The are useful as HSL inhibitors and may, for example, be used in treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, and obesity.

AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS

Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein n, m, A, R1 and R2 have the significance given in claim 1. The compounds are useful as HSL inhibitors for the treatment of diabetes dyslipidemia, atherosclerosis and obesity.